TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92427

Peptide_Name

WP2

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 14-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Hydroxamic acid N-terminal: Acetylation

Sequence

Ac-RLLRLLRLRRLLRL

FASTA

>TPDB92427|Antibacterial;Anticancer;Toxicity|length=14
Ac-RLLRLLRLRRLLRL

Formula C84H162N32O15

Absent Amino Acids ANDCEQGHIKMFPSTWYV

Common Amino Acids L

Mass 1860.42

PI 13.10

Basic Residues 6

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +6

Boman Index 0.38

Hydrophobicity 0.243

Aliphatic Index 222.86

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

0

A

6

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

8

L

0

K

0

M

0

F

0

P

0

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 6 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 8 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

14

Formula

C84H162N32O15

Mass

1860.42

PI

13.10

Net Charge

+6

Boman Index

0.38

Hydrophobicity

0.243

C_terminal_Modification

Hydroxamic acid

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Acetylation

Nature

Anticancer

Origin

Derived from RLL peptide

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 0.446±0.095 µM

Detail Source Activity Anticancer

Activity Measurement 0.446

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay HDAC inhibition assay

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 28.12 ± 1.5 µM

Detail Source Activity Anticancer

Activity Measurement 28.12

Target

Cancer Type Liver Cancer

Cell Line Huh-7

Tissue Affected Liver

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 34.05 ± 0.53 µM

Detail Source Activity Anticancer

Activity Measurement 34.05

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 42.6 ± 4.0 µM

Detail Source Activity Anticancer

Activity Measurement 42.6

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023